Not Every Patient Needs the Full Dose
When most people picture semaglutide for weight loss, they picture the titration schedule used in the STEP-1 clinical trial, doses climbing from 0.25 mg to 1 mg to 2.4 mg over months, delivering an average 14.9 percent body-weight reduction at 68 weeks, but also, for many patients, real side effects: nausea, fatigue, constipation, and GI distress that can make the first weeks of therapy uncomfortable.
That protocol is appropriate for patients with substantial weight-loss goals and strong clinical indications. It is not the only pattern patients pursue. Some licensed providers work with patients on microdose GLP-1 protocols, weekly semaglutide doses well below the FDA-approved starter dose of 0.25 mg, typically in the 0.05 mg to 0.20 mg range. Through Madison Meds, microdose semaglutide is available to eligible adults after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy, starting at $99 your first month with promo code SAVENOW and $125 per month ongoing.
Educational content. Not medical advice. A licensed-provider evaluation determines what is appropriate for any individual patient.
Off-Label Notice
Microdosing GLP-1 medications is an off-label practice not approved by the FDA. No dose below the lowest FDA-approved starting dose (0.25 mg for semaglutide) has been tested in a randomized controlled trial for safety or efficacy. Available evidence for subtherapeutic dosing is limited to observational reports, case series, and pharmacokinetic modeling. Any use should occur only after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. Educational content. Not medical advice. Individual results vary.
What Is Microdose GLP-1 Therapy?
Microdosing GLP-1 refers to administering weekly doses of semaglutide substantially lower than the conventional 0.25 mg starting dose used in Wegovy and Ozempic. Common microdose protocols begin in the 0.05 mg to 0.10 mg per week range and titrate slowly based on individual response. The convention emerged from compounding pharmacy practice and from providers looking for a lower-dose entry point for sensitive patients, or a maintenance option for patients who had already reached their weight-loss goals.
The stated goal of a microdose protocol is not maximum appetite suppression or fastest possible weight loss. It is what some practitioners call metabolic recalibration: using GLP-1 receptor agonism at a lower dose to support appetite regulation, reduce food-related preoccupation, and support insulin sensitivity, with the tradeoff that the average outcome is smaller than what standard-dose therapy delivers in randomized trials.
How GLP-1 Receptor Agonists Work
Semaglutide mimics glucagon-like peptide-1, a hormone naturally released by the gut after eating. When GLP-1 receptors are activated, several things happen at once:
- The pancreas releases insulin in response to elevated blood sugar.
- Glucagon secretion is suppressed, reducing blood glucose.
- Gastric emptying slows, meaning food stays in the stomach longer, producing sustained feelings of fullness.
- GLP-1 receptors in the hypothalamus and brainstem, the brain regions involved in appetite regulation, receive satiety signals, reducing hunger and the intrusive food-related thoughts that many patients describe as "food noise."
Semaglutide has a half-life of approximately 155 to 184 hours, so a single weekly injection maintains receptor activation across the week without the peaks and troughs of daily dosing.
What the Research Actually Shows
The strongest evidence for semaglutide in weight management comes from randomized controlled trials at standard doses. The STEP-1 trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with overweight or obesity without diabetes and studied semaglutide 2.4 mg weekly. Average body-weight reduction was 14.9 percent at 68 weeks. The STEP-4 maintenance trial (Rubino et al., JAMA 2021) then showed that patients who continued the 2.4 mg dose after a 20-week titration held their loss, while those switched to placebo regained an average 6.9 percent. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023) confirmed a 20 percent reduction in major adverse cardiac events at the same 2.4 mg dose over a median 39.8 months.
No comparable randomized trial data exists for weekly doses of 0.05 mg, 0.10 mg, or 0.20 mg. The FDA Wegovy prescribing information lists 0.25 mg as the lowest studied initiation dose. Clinical trial data for semaglutide shows a dose-response relationship, and even the 0.25 mg titration dose produced statistically significant weight loss versus placebo in STEP-1. What the trial data does not tell us is whether subtherapeutic doses below 0.25 mg produce clinically meaningful outcomes at the population level. Some patients report appetite changes at lower doses; others do not. Research is ongoing.
When licensed providers use a microdose protocol, they are extrapolating from pharmacokinetic modeling, observational reports, and clinical experience, not from a randomized trial designed to test the specific dose. The honest framing is that microdose semaglutide may support metabolic goals for eligible patients under medical supervision, with outcomes that are individual and not equivalent to trial-documented outcomes of standard-dose therapy.
Who Some Providers Consider a Microdose Protocol For
Microdose semaglutide is not a shortcut to standard-dose results. It is a distinct clinical option that some licensed providers consider for specific patient profiles:
Patients who want lower-dose appetite regulation, not maximum suppression. Some patients do not need to lose 15 to 20 percent of body weight. They want to take the edge off hunger and make healthier choices without feeling medicated.
Patients who were sensitive to side effects at the standard starter dose. GI side effects are the most common reason patients discontinue GLP-1 therapy. A microdose protocol under provider supervision may reduce the severity of nausea and GI distress for some patients, though this is based on observation rather than randomized comparison.
Patients in maintenance after significant weight loss. Once a patient has achieved their primary weight-loss goal, the highest studied maintenance dose may not be necessary. A lower maintenance dose may sustain results at lower cost, though the maintenance data from STEP-4 was collected at the 2.4 mg dose, not a microdose.
Patients with modest weight-loss goals. For patients slightly above their goal weight or focused on metabolic health rather than large-scale weight loss, a microdose may be proportionate to the goal.
New patients who want to titrate slowly. For patients uncertain about how their body will respond, some providers use a lower starting dose as a cautious on-ramp before moving into the FDA-approved 0.25 mg titration.
Microdose vs Standard Dosing
| Microdose GLP-1 | Standard GLP-1 (Wegovy) | |
|---|---|---|
| Starting dose | 0.05 to 0.10 mg/week | 0.25 mg/week |
| Titration speed | Slower, provider-guided | Fixed schedule per FDA label |
| Primary goal | Appetite regulation, lower-dose exposure | Significant weight loss |
| Randomized trial evidence | None specific to subtherapeutic dosing | STEP-1, STEP-4, SELECT and others |
| Regulatory status | Off-label compounded | FDA approved (Wegovy, Ozempic) |
| Best for | Sensitive patients, maintenance, modest goals | BMI-driven weight-loss targets |
| Madison Meds pricing | From $99 first month (SAVENOW), $125/month ongoing | From $99 first month (SAVENOW), $169/month ongoing |
What Patients Commonly Report
Microdose GLP-1 protocols are not a dramatic intervention. Patient-reported experiences commonly include:
- Reduced food noise. Many patients describe less constant mental chatter about food, snacking, and cravings within the first two to four weeks. Individual results vary.
- Portion changes. Meals feel satisfying with less food, and the drive to keep eating past fullness may diminish.
- Steadier energy patterns. Some patients report more stable blood sugar and steadier energy through the day.
- Gradual weight changes. Patients on microdose protocols typically describe modest, incremental changes rather than the trial-documented averages of standard-dose therapy. Outcomes are individual.
For patients in maintenance, the goal shifts from active loss to preservation, holding weight, stabilizing appetite, and preventing gradual regain. Note that the strongest maintenance evidence, from STEP-4, was collected at the 2.4 mg dose.
Common Microdose Protocols
Microdose schedules are set by a licensed provider and are individualized. A common pattern looks like this:
- Weeks 1 to 2: 0.05 mg weekly. Observe tolerance, hydration, and appetite response.
- Weeks 3 to 4: 0.10 mg weekly. Gradual increase if well tolerated.
- Weeks 5 to 6: 0.15 to 0.20 mg weekly. Only if further appetite regulation is needed.
- Week 7+: 0.25 mg or higher (moving into FDA-approved dosing) or a maintained microdose, based on goals, response, and provider guidance.
Many patients find their working range in the 0.10 to 0.20 mg tier. The right dose is the one that matches the patient's goals under provider supervision.
What a Microdose Does Not Do
- It is not a shortcut to standard-dose results. If a patient's goal requires the average outcome of STEP-1 or SELECT-scale therapy, a microdose is unlikely to deliver that.
- It is not "safer" simply because it is smaller. The same contraindications apply. Personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, severe GI disease, and other conditions remain relevant regardless of dose.
- It is not a research-grade protocol you can self-manage. Compounded semaglutide is a prescription product. Any protocol is set, monitored, and adjusted through a licensed-provider evaluation.
- It is not the same as Ozempic or Wegovy. Compounded semaglutide is not an FDA-approved finished drug product. It is dispensed by a US-licensed compounding pharmacy under federal and state pharmacy regulations.
Cost
Compounded semaglutide programs at Madison Meds start at $99 your first month with promo code SAVENOW. The microdose program is $125 per month ongoing; the standard-dose program is $169 per month ongoing. Brand-name semaglutide (Wegovy, Ozempic) without insurance can exceed $1,000 to $1,800 per month.
All Madison Meds pricing is all-inclusive: the licensed-provider evaluation, the compounded medication prepared at a US-licensed compounding pharmacy, supplies, and discreet home shipping.
The Honest Bottom Line
Microdose GLP-1 therapy sits in an evidence gap: the standard-dose protocols in Wegovy and Ozempic are supported by large randomized trials, and lower-dose compounded protocols are supported by clinical observation and pharmacokinetic reasoning but not by a controlled trial. Some patients find a microdose useful. Others need the full FDA-approved dosing to see meaningful change. The right answer is set by a licensed-provider evaluation, not by a website.
Educational content. Not medical advice. Individual results vary and outcomes are individual.
Curious if a microdose is right for you?
An independent licensed provider in the Madison Meds network will review your goals and medical history and recommend the right protocol. Compounded semaglutide microdose starts at $99 your first month with promo code SAVENOW.
See Microdose SemaglutideFrequently Asked Questions
What is a microdose of semaglutide?
A microdose of semaglutide generally refers to a weekly dose below the FDA-approved starter dose of 0.25 mg used in Wegovy and Ozempic. Compounded microdose protocols commonly run in the 0.05 mg to 0.20 mg per week range. The exact dose is set by a licensed provider based on the patient's goals, history, and response. Microdosing GLP-1 medications is an off-label practice not approved by the FDA.
Is low-dose semaglutide approved by the FDA?
No. The FDA has approved semaglutide (Wegovy, Ozempic) starting at a 0.25 mg weekly initiation dose. No dose below 0.25 mg has been tested in a randomized controlled trial for safety or efficacy. Compounded microdose protocols are dispensed by US-licensed compounding pharmacies after a licensed-provider evaluation, and any use should occur under medical supervision. Educational content. Not medical advice.
Who might consider a microdose of semaglutide?
Microdose semaglutide may be considered for eligible patients who are sensitive to GLP-1 side effects at the standard starter dose, want a lower-dose entry into therapy, have a modest weight-loss goal, are using GLP-1 therapy primarily for metabolic support, or want a maintenance protocol after reaching a previous weight goal. The final decision is made during a licensed-provider evaluation.
How much weight loss can you expect on a microdose of semaglutide?
Available data for weekly doses below 0.25 mg is limited to observational reports and pharmacokinetic modeling; there is no randomized controlled trial. Patients on microdose protocols commonly report 3 to 8 percent of body weight over six months, compared with the 14.9 percent average seen in the STEP-1 trial for standard-dose semaglutide 2.4 mg at 68 weeks. Individual results vary.
Is microdose semaglutide cheaper than standard-dose semaglutide?
Yes. Because the active ingredient quantity per month is lower, compounded microdose semaglutide is typically less expensive than standard-dose compounded semaglutide. Madison Meds compounded semaglutide microdose starts at $99 your first month with promo code SAVENOW, and $125 per month ongoing.
Can you switch from microdose to a standard dose later?
Yes. Many patients start at a microdose for tolerability and titrate upward over time. The licensed-provider evaluation determines when and how to adjust the protocol, and updates are made through follow-up visits. There is no requirement to escalate if the microdose is producing your desired result.
What does the research show about microdose semaglutide?
Every published randomized controlled trial for weight management, including STEP-1 (Wilding et al., NEJM 2021), STEP-4 (Rubino et al., JAMA 2021), and SELECT (Lincoff et al., NEJM 2023), started at 0.25 mg weekly and titrated up to a 2.4 mg maintenance dose. No comparable randomized data exists for subtherapeutic doses below 0.25 mg. Available evidence for microdose protocols is limited to observational reports and pharmacokinetic modeling. Research is ongoing, and outcomes are individual.
Compounded medications are not FDA-approved finished drug products. This article is Educational content and is Not medical advice. Compounded semaglutide is available through Madison Meds after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. A licensed provider will review your full medical history before any prescription, and not all patients are appropriate candidates for GLP-1 therapy. The dose ranges, weight-loss figures, and timelines discussed are general references; individual results vary and outcomes are individual.